Brassinosteroids inhibit in vitro angiogenesis in human endothelial cells
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
22974826
DOI
10.1016/j.steroids.2012.08.011
PII: S0039-128X(12)00239-5
Knihovny.cz E-resources
- MeSH
- Estrogen Receptor alpha metabolism MeSH
- Estrogen Receptor beta metabolism MeSH
- Brassinosteroids metabolism pharmacology MeSH
- Human Umbilical Vein Endothelial Cells drug effects metabolism MeSH
- Neovascularization, Physiologic drug effects MeSH
- Angiogenesis Inhibitors metabolism pharmacology MeSH
- Humans MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Estrogen Receptor alpha MeSH
- Estrogen Receptor beta MeSH
- Brassinosteroids MeSH
- Angiogenesis Inhibitors MeSH
Antiangiogenic activity of the brassinosteroid plant hormones (BRs) and their derivative cholestanon was investigated in human umbilical vein endothelial cells (HUVEC) and in human microvascular endothelial cells (HMEC-1). 24-Epibrassinolide and 28-homocastasterone from group of 21 tested natural BRs inhibited migration of HUVEC cells. Seven tested BRs decreased the number of tubes significantly. Synthetic analogue cholestanon inhibited angiogenesis in vitro more effectively than natural BRs. Because of the similarity of BRs to human steroids, we have also studied interactions of BRs with human steroid receptors. Synthetic BRs cholestanon showed agonistic effects on estrogen-receptor-α, estrogen-receptor-β and androgen receptor. Of the natural BRs, 24-epibrassinolide was found to be a weak antagonist of estrogen-receptor-α (ERα). Our results provide the first evidence that large group of BRs can inhibit in vitro angiogenesis of primary endothelial cells. BRs constitute a novel group of human steroid receptor activators or inhibitors with capacity to inhibit angiogenesis.
References provided by Crossref.org